With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.351498-10-7,6,6′-((1E,1’E)-((2,3-Dimethylbutane-2,3-diyl)bis(azanylylidene))bis(methanylylidene))bis(2,4-di-tert-butylphenol),as a common compound, the synthetic route is as follows.
A 50 ml. flask was charged withLambda/,Lambda/-bis(3,5-di-te/t-butylsalicylidene)-1 ,1 ,2,2-tetramethylethenediamine (0.4302 g, 0.78 mmol, 1.0 equiv), EtOH (17 ml_), and Co(OAc)2 (0.1385 g, 0.78 mmol, 1.0 equiv). The mixture was degassed and then heated to reflux under nitrogen for 3 h, cooled to room temperature. The precipitate was filtered and the purple solid was washed with EtOH (10 ml.) and dried under high vacuum to give 0.3533 g (75%) of the cobalt(ll) complex.
As the paragraph descriping shows that 351498-10-7 is playing an increasingly important role.
Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; CLAREMON, David, A.; LEFTHERIS, Katerina; ZHUANG, Linghang; TICE, Colin, M.; SINGH, Suresh, B.; YE, Yuanjie; WO2011/11123; (2011); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare